查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1937888

全球氣喘藥物市場規模、佔有率、趨勢和成長分析報告（2026-2034）

Global Asthma Therapeutics Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計氣喘藥物市場規模將從 2025 年的 348.4 億美元成長到 2034 年的 539.1 億美元，2026 年至 2034 年的複合年成長率為 4.97%。

氣喘藥物市場正經歷顯著成長，這主要得益於氣喘盛行率的上升以及對有效治療方法需求的不斷成長。隨著人們對氣喘管理的認知不斷提高，醫療服務提供者正致力於制定個人化的治療方案，以滿足每位患者的獨特需求。包括生物製藥和標靶治療在內的氣喘藥物創新正在改變氣喘管理的格局，為重度氣喘和難治性氣喘患者帶來新的希望。此外，智慧吸入器和數位健康解決方案的開發也為提高用藥依從性和監測效果提供了有力支持。

此外，對預防性護理和早期療育的日益重視正在影響氣喘藥物市場。隨著醫療保健系統優先考慮積極主動的管理策略，對有效氣喘藥物的需求正在飆升。同時，對病患教育和自我管理的日益重視，使病患能夠更好地控制氣喘，從而改善治療效果並降低醫療成本。

此外，遠端醫療和遠距監測技術的興起正在促進氣喘管理的改善。患者現在無需親自就診即可獲得醫療專業人員的諮詢和後續觀察，從而更輕鬆地控制症狀。在新冠肺炎疫情的背景下，這一趨勢尤其重要，因為遠端醫療已成為必不可少的手段。總之，氣喘藥物市場有望實現強勁成長，其特點是創新、注重個人化醫療以及致力於改善氣喘患者的生活品質。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 繪製滲透率和成長前景圖
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制
    • 市場機遇
    • 市場問題
  • 波特五力分析
  • PESTLE分析

4. 全球氣喘藥物市場（依藥物類別分類）

  • 市場分析、洞察與預測
  • 聯合治療（吸入性糖皮質激素/長效BETA2受體激動劑）
  • 長效BETA2受體激動劑（LABA）
  • 短效BETA2受體激動劑（SABA）
  • 吸入性皮質類固醇（ICS）
  • 口服和靜脈注射皮質類固醇
  • 白三烯調節劑
  • 其他

5. 全球氣喘藥物市場（依治療類型分類）

  • 市場分析、洞察與預測
  • 長期氣喘控制藥物
  • 快速起效（急救）藥物

6. 全球氣喘藥物市場依給藥途徑分類

  • 市場分析、洞察與預測
  • 局部的
  • 口服
  • 注射

7. 全球氣喘藥物市場（依分銷管道分類）

  • 市場分析、洞察與預測
  • 實體店面
  • 醫院藥房
  • 電子商務

8. 全球氣喘藥物市場依最終用途分類

  • 市場分析、洞察與預測
  • 醫院和診所
  • 門診手術中心
  • 居家醫療環境

9. 全球氣喘藥物市場（依地區分類）

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第10章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商格局（基於現有資訊）
  • 策略規劃

第11章 公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • AstraZeneca
    • Boehringer Ingelheim
    • Cipla Ltd
    • Covis Pharma
    • GSK Plc
    • Merck & Co. Inc
    • Novartis Pharmaceuticals Corporation
    • Regeneron Pharmaceuticals Inc
    • Sanofi
    • Teva Pharmaceutical Industries Ltd
簡介目錄
Product Code: VMR11217451

The Asthma Therapeutics Market size is expected to reach USD 53.91 Billion in 2034 from USD 34.84 Billion (2025) growing at a CAGR of 4.97% during 2026-2034.

The asthma therapeutics market is experiencing substantial growth, driven by the increasing prevalence of asthma and the rising demand for effective treatment options. As awareness of asthma management improves, healthcare providers are focusing on personalized treatment plans that address the unique needs of each patient. Innovations in asthma therapeutics, including biologics and targeted therapies, are transforming the landscape of asthma management, offering new hope for patients with severe and uncontrolled asthma. These advancements are complemented by the development of smart inhalers and digital health solutions that enhance medication adherence and monitoring.

Moreover, the growing emphasis on preventive care and early intervention is influencing the asthma therapeutics market. As healthcare systems prioritize proactive management strategies, the demand for effective asthma medications is surging. Additionally, the increasing focus on patient education and self-management is empowering individuals to take control of their asthma, leading to improved outcomes and reduced healthcare costs.

Furthermore, the rise of telemedicine and remote monitoring technologies is facilitating better asthma management. Patients can now access healthcare professionals for consultations and follow-ups without the need for in-person visits, making it easier to manage their condition. This trend is particularly relevant in the context of the COVID-19 pandemic, where remote care has become essential. In conclusion, the asthma therapeutics market is set for robust growth, characterized by innovation, a focus on personalized care, and a commitment to improving the quality of life for asthma patients.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

  • Combination Therapies (ICS/LABAs)
  • Long-Acting Beta Agonists (LABAs)
  • Short-Acting Beta Agonists (SABAs)
  • Inhaled Corticosteroids (ICS)
  • Oral And Intravenous Corticosteroids
  • Leukotriene Modifiers
  • Other

By Treatment Type

  • Long-Term Asthma Control Medications
  • Quick-Relief (Rescue) Medications

By Route Of Administration

  • Topical
  • Oral
  • Injectables

By Distribution Channel

  • Brick & Mortar
  • Hospital Pharmacies
  • E-Commerce

By End-Use

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Homecare Settings

COMPANIES PROFILED

  • AstraZeneca, Boehringer Ingelheim, Cipla Ltd, Covis Pharma, GSK plc, Merck Co Inc, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals Inc, Sanofi, Teva Pharmaceutical Industries Ltd

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ASTHMA THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Class
  • 4.2. Combination Therapies (ICS/LABAs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Long-Acting Beta Agonists (LABAs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Short-Acting Beta Agonists (SABAs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Inhaled Corticosteroids (ICS) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Oral And Intravenous Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Leukotriene Modifiers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.8. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ASTHMA THERAPEUTICS MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Treatment Type
  • 5.2. Long-Term Asthma Control Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Quick-Relief (Rescue) Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ASTHMA THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Injectables Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ASTHMA THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Distribution Channel
  • 7.2. Brick & Mortar Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. E-Commerce Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ASTHMA THERAPEUTICS MARKET: BY END-USE 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast End-use
  • 8.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Ambulatory Surgical Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.4. Homecare Settings Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ASTHMA THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.2.1 By Drug Class
    • 9.2.2 By Treatment Type
    • 9.2.3 By Route Of Administration
    • 9.2.4 By Distribution Channel
    • 9.2.5 By End-use
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.3.1 By Drug Class
    • 9.3.2 By Treatment Type
    • 9.3.3 By Route Of Administration
    • 9.3.4 By Distribution Channel
    • 9.3.5 By End-use
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.4.1 By Drug Class
    • 9.4.2 By Treatment Type
    • 9.4.3 By Route Of Administration
    • 9.4.4 By Distribution Channel
    • 9.4.5 By End-use
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.5.1 By Drug Class
    • 9.5.2 By Treatment Type
    • 9.5.3 By Route Of Administration
    • 9.5.4 By Distribution Channel
    • 9.5.5 By End-use
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 South East Asia
    • 9.5.11 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.6.1 By Drug Class
    • 9.6.2 By Treatment Type
    • 9.6.3 By Route Of Administration
    • 9.6.4 By Distribution Channel
    • 9.6.5 By End-use
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL ASTHMA THERAPEUTICS INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 AstraZeneca
    • 11.2.2 Boehringer Ingelheim
    • 11.2.3 Cipla Ltd
    • 11.2.4 Covis Pharma
    • 11.2.5 GSK Plc
    • 11.2.6 Merck & Co. Inc
    • 11.2.7 Novartis Pharmaceuticals Corporation
    • 11.2.8 Regeneron Pharmaceuticals Inc
    • 11.2.9 Sanofi
    • 11.2.10 Teva Pharmaceutical Industries Ltd